Research location
Eggenfelden
Germany
Advertisement
Research activity in Eggenfelden
GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 18 trials and 18 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Eggenfelden
18 linked trials · page 1 of 1Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26 · 1 site observation
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation
RECRUITING
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanNCT05573893 · 2023-09-12 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerNCT05306041 · 2023-01-02 · 1 site observation
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 · 2022-12-16 · 1 site observation
RECRUITING
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.NCT04767594 · 2020-10-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and AustriaNCT02619929 · 2016-02-01 · 1 site observation
COMPLETED
PALbociclib CoLlaborative Adjuvant StudyNCT02513394 · 2015-08-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerNCT02032823 · 2014-04-22 · 1 site observation
ACTIVE_NOT_RECRUITING
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01574651 · 2012-05-01 · 1 site observation
COMPLETED
A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast CancerNCT01171417 · 2010-08-01 · 1 site observation
COMPLETED
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)NCT01285167 · 2010-08-01 · 1 site observation
COMPLETED
A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)NCT00900731 · 2009-06-01 · 1 site observation
COMPLETED
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active ControlNCT00567996 · 2007-11-01 · 1 site observation
COMPLETED
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DNCT00490139 · 2007-05-16 · 1 site observation
COMPLETED
Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different SeverityNCT00274573 · 2002-03-01 · 1 site observation
COMPLETED
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.NCT00287534 · 1996-11-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.